Search

Displaying results 51 - 60 of 206 in total
  1. Drug

    Dimetacrine

    go.drugbank.com/drugs/DB08996
    ApprovedWithdrawn

    Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.

  2. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare.

  3. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.

  4. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.

  5. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977.

  6. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe

  7. Drug

    Bemiparin

    go.drugbank.com/drugs/DB09258
    ApprovedInvestigationalWithdrawn

    Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which i...

  8. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.

  9. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European

  10. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and